These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31027430)

  • 21. Multimodal interventions for bundle implementation to decrease central line-associated bloodstream infections in adult intensive care units in a teaching hospital in Taiwan, 2009-2013.
    Lin WP; Chang YC; Wu UI; Hung MC; Chuang PY; Wang JT; Sheng WH; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2018 Oct; 51(5):644-651. PubMed ID: 28888825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The applicability of the central line-associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients.
    van den Bosch CH; Frakking FNJ; Loeffen YGT; van Tinteren H; van der Steeg AFW; Wijnen MHWA; van de Wetering MD; van der Bruggen JT
    Eur J Haematol; 2024 May; 112(5):832-839. PubMed ID: 38294085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology-oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates.
    Chong CY; Ong RY; Seah VX; Tan NW; Chan MY; Soh SY; Ong C; Lim AS; Thoon KC
    J Paediatr Child Health; 2020 Jan; 56(1):123-129. PubMed ID: 31145505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel risk factors for central-line associated bloodstream infections in critically ill children.
    Woods-Hill CZ; Srinivasan L; Schriver E; Haj-Hassan T; Bezpalko O; Sammons JS
    Infect Control Hosp Epidemiol; 2020 Jan; 41(1):67-72. PubMed ID: 31685049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central-line-associated bloodstream infections and central-line-associated non-CLABSI complications among pediatric oncology patients.
    Kelada AS; Foster TB; Gagliano GC; Worley S; Tang A; Arakoni VA; Foster CB
    Infect Control Hosp Epidemiol; 2023 Mar; 44(3):377-383. PubMed ID: 35475427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ambulatory pediatric oncology CLABSIs: epidemiology and risk factors.
    Rinke ML; Milstone AM; Chen AR; Mirski K; Bundy DG; Colantuoni E; Pehar M; Herpst C; Miller MR
    Pediatr Blood Cancer; 2013 Nov; 60(11):1882-9. PubMed ID: 23881643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Disinfection Cap to Reduce Central-Line-Associated Bloodstream Infection and Blood Culture Contamination Among Hematology-Oncology Patients.
    Kamboj M; Blair R; Bell N; Son C; Huang YT; Dowling M; Lipitz-Snyderman A; Eagan J; Sepkowitz K
    Infect Control Hosp Epidemiol; 2015 Dec; 36(12):1401-8. PubMed ID: 26394849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-level Intervention Program - A Quality Improvement Initiative to Decrease Central Line-Associated Bloodstream Infections in the Pediatric Acute and Hematology/Oncology Units.
    Santos KMB; Husain SS; Torres V; Huang CC; Jacob E
    J Pediatr Nurs; 2019; 48():106-113. PubMed ID: 31377635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is zero central line-associated bloodstream infection rate sustainable? A 5-year perspective.
    Erdei C; McAvoy LL; Gupta M; Pereira S; McGowan EC
    Pediatrics; 2015 Jun; 135(6):e1485-93. PubMed ID: 25986020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacterial bloodstream infections in pediatric allogeneic hematopoietic stem cell recipients before and after implementation of a central line-associated bloodstream infection protocol: A single-center experience.
    Chang AK; Foca MD; Jin Z; Vasudev R; Laird M; Schwartz S; Qureshi M; Kolb M; Levinson A; Bhatia M; Kung A; Garvin J; George D; Della-Latta P; Whittier S; Saiman L; Satwani P
    Am J Infect Control; 2016 Dec; 44(12):1650-1655. PubMed ID: 27378008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: A single-institution report.
    Rogers AE; Eisenman KM; Dolan SA; Belderson KM; Zauche JR; Tong S; Gralla J; Hilden JM; Wang M; Maloney KW; Dominguez SR
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27616655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in Central Line-Associated Bloodstream Infection (CLABSI) Rates Following Implementation of Levofloxacin Prophylaxis for Children and Adolescents With High-Risk Leukemia.
    Linder LA; Gerdy C; Jo Y; Stark C; Wilson A
    J Pediatr Hematol Oncol Nurs; 2023; 40(2):69-81. PubMed ID: 36358024
    [No Abstract]   [Full Text] [Related]  

  • 33. Attributable length of stay and cost for pediatric and neonatal central line-associated bloodstream infections in Greece.
    Karagiannidou S; Zaoutis T; Maniadakis N; Papaevangelou V; Kourlaba G
    J Infect Public Health; 2019; 12(3):372-379. PubMed ID: 30616938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics, costs, and outcomes associated with central-line-associated bloodstream infection and hospital-onset bacteremia and fungemia in US hospitals.
    Yu KC; Jung M; Ai C
    Infect Control Hosp Epidemiol; 2023 Dec; 44(12):1920-1926. PubMed ID: 37424226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of multiple concurrent central venous catheters on central line-associated bloodstream infections.
    Concannon C; van Wijngaarden E; Stevens V; Dumyati G
    Infect Control Hosp Epidemiol; 2014 Sep; 35(9):1140-6. PubMed ID: 25111922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The descriptive epidemiology of central line-associated bloodstream infection among patients in non-intensive care unit settings.
    Tedja R; Gordon SM; Fatica C; Fraser TG
    Infect Control Hosp Epidemiol; 2014 Feb; 35(2):164-8. PubMed ID: 24442079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bringing central line-associated bloodstream infection prevention home: CLABSI definitions and prevention policies in home health care agencies.
    Rinke ML; Bundy DG; Milstone AM; Deuber K; Chen AR; Colantuoni E; Miller MR
    Jt Comm J Qual Patient Saf; 2013 Aug; 39(8):361-70. PubMed ID: 23991509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethanol lock therapy in pediatric hematology and oncology.
    Wolf J; Shenep JL; Clifford V; Curtis N; Flynn PM
    Pediatr Blood Cancer; 2013 Jan; 60(1):18-25. PubMed ID: 22911535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central line-associated bloodstream infections in non-ICU inpatient wards: a 2-year analysis.
    Rhee Y; Heung M; Chen B; Chenoweth CE
    Infect Control Hosp Epidemiol; 2015 Apr; 36(4):424-30. PubMed ID: 25782897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central line-associated bloodstream infections in adult hematology patients with febrile neutropenia: an evaluation of surveillance definitions using differential time to blood culture positivity.
    Freeman JT; Elinder-Camburn A; McClymont C; Anderson DJ; Bilkey M; Williamson DA; Berkahn L; Roberts SA
    Infect Control Hosp Epidemiol; 2013 Jan; 34(1):89-92. PubMed ID: 23221198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.